RBM39 inhibitors induced the intron retention of mRNA of homologous recombination repair (HRR) genes in cancers with homologous recombination deficiency (HRD), causing a synthetic lethality of HRD-positive tumor cells [43]. Here, RBM39 is linked to hypoparathyroidism-retardation-dysmorphism syndrome.